Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aardvark Therapeutics, Inc.
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 11, 2026
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
May 21, 2026
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 10, 2026
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
April 30, 2026
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 24, 2026
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 10, 2026
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
March 10, 2026
Aardvark Therapeutics Announces Leadership Appointments
March 10, 2026